Synokem gets CDSCO Panel Nod To Study FDC Dapagliflozin plus Sacubitril plus Valsartan
New Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence (BE) study of the fixed-dose combination (FDC) Dapagliflozin Propanediol Monohydrate plus Sacubitril plus Valsartan Sodium Salt Film Coated Tablets. This came after Synokem Pharmaceutical presented its […]